Advanced Gene Transfer Company, Inc.

Rochester, NY · Biotech · Private

Gene transfer technology for programming CAR-T cells to treat HIV by efficiently delivering genetic material into primary T-cells

Grants
$549K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Carbon Nanotube-Mediated Gene Transfer into Human T-cells for CAR-T HIV Therapy$273,754
Federal grantDepartment of Health and Human Services · Phase I · Enhanced CRISPR gene editing in pluripotent stem cells using carbon nanotube arrays$275,045
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2670AFFINITY MOLECULES LLC——
2671Paralos Bioscience Inc.—$50K
2672POTOMAC AFFINITY PROTEIN LLC——
2673Advanced Gene Transfer Company, Inc.——
2674ITERION THERAPEUTICS INC. ——
2675Qu Biologics Inc.—$49K
2676Sequence46, LLC—$48K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.